Japanese (NIKKEI) Biotech Industry Analysis

Industry Valuation and Performance

Has the Japanese Biotech Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Thu, 27 Aug 2026	JP¥954.1b	JP¥159.3b	-JP¥42,646,059,682.00	42.1x	-22.4x	6x
Sat, 25 Jul 2026	JP¥814.3b	JP¥159.3b	-JP¥44,557,736,682.00	28.4x	-18.3x	5.1x
Mon, 22 Jun 2026	JP¥779.8b	JP¥159.3b	-JP¥42,098,631,682.00	28.2x	-18.5x	4.9x
Wed, 20 May 2026	JP¥1.1t	JP¥198.8b	-JP¥55,074,660,682.00	47.8x	-19.6x	5.4x
Fri, 17 Apr 2026	JP¥1.2t	JP¥202.7b	-JP¥49,292,644,682.00	64x	-24.1x	5.9x
Sun, 15 Mar 2026	JP¥1.2t	JP¥202.7b	-JP¥49,063,050,682.00	64.3x	-24.4x	5.9x
Tue, 10 Feb 2026	JP¥1.1t	JP¥198.5b	-JP¥70,522,747,000.00	58.1x	-15.4x	5.5x
Thu, 08 Jan 2026	JP¥1.0t	JP¥198.7b	-JP¥70,727,387,000.00	55.1x	-14.6x	5.2x
Sat, 06 Dec 2025	JP¥979.6b	JP¥196.3b	-JP¥69,395,659,000.00	48.6x	-14.1x	5x
Mon, 03 Nov 2025	JP¥1.1t	JP¥197.5b	-JP¥65,616,668,000.00	62.5x	-16.9x	5.6x
Wed, 01 Oct 2025	JP¥1.1t	JP¥197.7b	-JP¥65,794,561,000.00	65.2x	-17.1x	5.7x
Fri, 29 Aug 2025	JP¥1.1t	JP¥193.5b	-JP¥68,135,862,000.00	128x	-16.7x	5.9x
Sun, 27 Jul 2025	JP¥1.2t	JP¥218.2b	-JP¥46,531,847,000.00	105.2x	-24.9x	5.3x
Tue, 24 Jun 2025	JP¥1.2t	JP¥218.2b	-JP¥43,673,263,000.00	100.1x	-26.6x	5.3x
Thu, 22 May 2025	JP¥1.1t	JP¥214.6b	-JP¥40,489,412,000.00	12.7x	-27.5x	5.2x
Sat, 19 Apr 2025	JP¥1.1t	JP¥207.7b	-JP¥38,921,205,000.00	14.2x	-27.3x	5.1x
Mon, 17 Mar 2025	JP¥1.0t	JP¥207.8b	-JP¥39,316,682,000.00	16.2x	-26.2x	5x
Wed, 12 Feb 2025	JP¥1.0t	JP¥207.5b	-JP¥13,501,659,000.00	21.1x	-75.8x	4.9x
Fri, 10 Jan 2025	JP¥1.1t	JP¥207.3b	-JP¥13,531,081,000.00	21.6x	-78.6x	5.1x
Sun, 08 Dec 2024	JP¥1.1t	JP¥207.2b	-JP¥12,080,899,000.00	22.7x	-88.8x	5.2x
Tue, 05 Nov 2024	JP¥1.1t	JP¥214.4b	-JP¥3,930,528,000.00	22.4x	-273.1x	5x
Thu, 03 Oct 2024	JP¥1.1t	JP¥214.3b	-JP¥2,078,229,000.00	22.5x	-552.4x	5.4x
Sat, 31 Aug 2024	JP¥1.1t	JP¥210.1b	-JP¥469,229,000.00	16.9x	-2347.4x	5.2x
Mon, 29 Jul 2024	JP¥1.1t	JP¥187.7b	-JP¥15,871,901,000.00	92.8x	-66.4x	5.6x
Wed, 26 Jun 2024	JP¥926.4b	JP¥187.7b	-JP¥15,773,284,000.00	85.7x	-58.7x	4.9x
Fri, 24 May 2024	JP¥767.3b	JP¥195.7b	-JP¥14,072,545,000.00	92.2x	-54.5x	3.9x
Sun, 21 Apr 2024	JP¥705.7b	JP¥194.2b	-JP¥15,746,877,000.00	62.7x	-44.8x	3.6x
Tue, 19 Mar 2024	JP¥774.6b	JP¥194.2b	-JP¥18,497,301,000.00	58.7x	-41.9x	4x
Thu, 15 Feb 2024	JP¥735.5b	JP¥222.6b	-JP¥10,744,799,000.00	16.8x	-68.4x	3.3x
Sat, 13 Jan 2024	JP¥821.1b	JP¥222.3b	-JP¥12,668,455,000.00	17.6x	-64.8x	3.7x
Mon, 11 Dec 2023	JP¥754.7b	JP¥221.9b	-JP¥12,426,487,000.00	15.8x	-60.7x	3.4x
Wed, 08 Nov 2023	JP¥758.3b	JP¥223.0b	-JP¥14,350,085,000.00	19.9x	-52.8x	3.4x
Fri, 06 Oct 2023	JP¥823.8b	JP¥223.0b	-JP¥14,518,735,000.00	24x	-56.7x	3.7x
Sun, 03 Sep 2023	JP¥907.0b	JP¥225.1b	-JP¥19,814,131,000.00	48.8x	-45.8x	4x

Current Industry PE

Investors are optimistic on the Japanese Biotechs industry, and appear confident in long term growth rates.

The 3-year average PS ratio of 4.9x is lower than the industry's current PS ratio of 6.0x.

Past Earnings Growth

The earnings for companies in the Biotechs industry have deteriorated over the last three years.
Revenues have also declined 11% per year.
This means overall sales from these companies are declining and losses are subsequently expanding as well.

Industry Trends

Which industries have driven the changes within the Japanese Healthcare industry?


JP Market	2.37%
Healthcare	1.79%
Biotech	4.78%
Biotech	4.78%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
4588 Oncolys BioPharma	JP¥4.02k	17.5% +JP¥18.2b	510.0%	PS4146x
4587 PeptiDream	JP¥1.11k	7.9% +JP¥10.5b	-29.9%	PS7.4x
219A Heartseed	JP¥2.32k	15.5% +JP¥7.1b	-33.6%	PE89.7x
4894 Cuorips	JP¥5.49k	11.8% +JP¥4.8b	-21.6%	PS213.9x
4593 Healios K.K	JP¥282.00	8.9% +JP¥3.1b	-41.1%	PS514.5x

Oncolys BioPharma Receives Full Marketing Approval in Japan for Telomelysin Injection for the Treatment of Esophageal Cancer

Oncolys BioPharma Inc. announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for Telomelysin Injection (generic name: suratadenoturev; development code: OBP-301), an oncolytic adenovirus product, for the treatment of esophageal cancer in patients who are not eligible for curative resection or chemoradiotherapy. Telomelysin is the world’s first oncolytic adenovirus product approved for the treatment of esophageal cancer. The approval was granted as a full marketing approval, rather than conditional or time-limited approval, following MHLW review of data from Oncolys’ pivotal clinical study conducted at 17 sites in Japan. Oncolys submitted the marketing authorization application on December 15, 2025. Telomelysin is designed to selectively replicate in and lyse cancer cells by utilizing telomerase activity, which is highly expressed in many malignant tumors. Through this mechanism, Telomelysin is intended to offer a new treatment option for patients with esophageal cancer who have limited therapeutic alternatives. Under the sales partnership agreement entered into in February 2024, FUJIFILM Toyama Chemical Co. Ltd. will be responsible for the commercialization of Telomelysin in Japan following National Health Insurance price listing. As a result of this approval, Oncolys will receive a milestone payment from FUJIFILM Toyama Chemical, which is expected to be recorded as revenue for the fiscal year ending December 31, 2026. Oncolys also expects to receive the remaining balance of the payment related to product supply during the current fiscal year. This amount will initially be recorded as advances received, or contract liabilities, on Oncolys’ balance sheet and is expected to be recognized as revenue progressively following the commercial launch of Telomelysin. The amounts have not been disclosed. Oncolys plans to launch Telomelysin in Japan in fiscal year 2026 following National Health Insurance price listing. The impact of this approval on Oncolys’ financial results for the current fiscal year is currently under review. Telomelysin is an oncolytic adenovirus designed to selectively replicate in cancer cells through activation of the human telomerase reverse transcriptase promoter. Following intratumoral administration, Telomelysin replicates within cancer cells and induces tumor cell lysis. Oncolys has been developing Telomelysin as a novel cancer therapy, with a focus on indications in which local tumor control and combination with radiotherapy may provide clinical benefit.

Japanese (NIKKEI) Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Chordia Therapeutics Inc. announced that it expects to receive ¥6.07926 million in funding from Nomura Holdings, Inc.

3-D Matrix, Ltd. to Report Q1, 2027 Results on Sep 10, 2026

Consensus revenue estimates fall by 26%

New minor risk - Market cap size

New major risk - Financial position

Second quarter 2026 earnings released: EPS: JP¥2.49 (vs JP¥7.62 loss in 2Q 2025)

New major risk - Financial position

The PeptiDream Inc. (TSE:4587) Half-Yearly Results Are Out And Analysts Have Published New Forecasts

First quarter 2027 earnings released: EPS: JP¥1.28 (vs JP¥5.97 loss in 1Q 2026)

SanBio Company Limited to Report Q2, 2027 Results on Sep 14, 2026

Less than half of directors are independent

New major risk - Share price stability

New minor risk - Financial data availability

TMS Co., Ltd. to Report Q2, 2026 Results on Aug 14, 2026

Oncolys BioPharma Receives Full Marketing Approval in Japan for Telomelysin Injection for the Treatment of Esophageal Cancer

Innovacell Inc., Annual General Meeting, Mar 26, 2026